Literature DB >> 22811833

Splenectomy ameliorates hematologic toxicity of hyperthermic intraperitoneal chemotherapy.

Robert D Becher1, Perry Shen, John H Stewart, Greg Russell, Joel F Bradley, Edward A Levine.   

Abstract

BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is a promising modality for peritoneal carcinomatosis. Splenectomy is frequently required, however effect upon hematotoxicity is unknown.
METHODS: 195 patients undergoing the procedure were evaluated and granulocyte colony stimulating factor administered for white blood cell counts <4.0.
RESULTS: 52% of 195 underwent splenectomy; average white blood cell and platelet nadirs were 6.1,172. Non-splenectomy patients averaged white blood cell nadir 4.6, platelet nadir 164.1. Granulocyte colony stimulating factor administered in 29% of splenectomy, 43% of non-splenectomy (P=0.043).
CONCLUSION: Splenectomy ameliorates hematotoxicity of hyperthermic intraperitoneal chemotherapy and significantly reduces post-operative granulocyte colony stimulating factor requirements.

Entities:  

Keywords:  hyperthermic intraperitoneal chemotherapy; peritoneal carcinomatosis; splenectomy

Year:  2011        PMID: 22811833      PMCID: PMC3397603          DOI: 10.3978/j.issn.2078-6891.2011.011

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  26 in total

1.  Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion.

Authors:  Syed A Ahmad; Joseph Kim; Jeffrey J Sussman; Debbie A Soldano; Linda J Pennington; Laura E James; Andrew M Lowy
Journal:  Ann Surg Oncol       Date:  2004-04       Impact factor: 5.344

2.  Hematologic changes after splenectomy for cytoreduction: implications for predicting infection and effects on chemotherapy.

Authors:  M A Bidus; T C Krivak; R Howard; G S Rose; J Cosin; L Dainty; J C Elkas
Journal:  Int J Gynecol Cancer       Date:  2006 Nov-Dec       Impact factor: 3.437

3.  Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.

Authors:  B Sadeghi; C Arvieux; O Glehen; A C Beaujard; M Rivoire; J Baulieux; E Fontaumard; A Brachet; J L Caillot; J L Faure; J Porcheron; J L Peix; Y François; J Vignal; F N Gilly
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

4.  Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.

Authors:  D Elias; M Bonnay; J M Puizillou; S Antoun; S Demirdjian; Otmany A El; J P Pignon; L Drouard-Troalen; J F Ouellet; M Ducreux
Journal:  Ann Oncol       Date:  2002-02       Impact factor: 32.976

5.  In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C.

Authors:  B Barlogie; P M Corry; B Drewinko
Journal:  Cancer Res       Date:  1980-04       Impact factor: 12.701

6.  White blood cell and platelet counts can be used to differentiate between infection and the normal response after splenectomy for trauma: prospective validation.

Authors:  Janie Weng; Carlos V R Brown; Peter Rhee; Ali Salim; Linda Chan; Demetrios Demetriades; George C Velmahos
Journal:  J Trauma       Date:  2005-11

7.  Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells.

Authors:  B A Teicher; C D Kowal; K A Kennedy; A C Sartorelli
Journal:  Cancer Res       Date:  1981-03       Impact factor: 12.701

8.  Peritoneal carcinomatosis from colorectal cancer.

Authors:  D G Jayne; S Fook; C Loi; F Seow-Choen
Journal:  Br J Surg       Date:  2002-12       Impact factor: 6.939

9.  A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers.

Authors:  John H Stewart; Perry Shen; Greg Russell; Joyce Fenstermaker; Libby McWilliams; Faith M Coldrun; Keith E Levine; Bradley T Jones; Edward A Levine
Journal:  Ann Surg Oncol       Date:  2008-05-21       Impact factor: 5.344

10.  Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C.

Authors:  Laura A Lambert; Terri S Armstrong; J Jack Lee; Suyu Liu; Matthew H G Katz; Cathy Eng; Robert A Wolff; Melissa L Tortorice; Pier Tansey; Santiago Gonzalez-Moreno; Donald H Lambert; Paul F Mansfield
Journal:  Ann Surg Oncol       Date:  2009-05-28       Impact factor: 5.344

View more
  6 in total

1.  Splenectomy revisited in 2011: Impact on hematologic toxicities while performing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Nancy Deslauriers; Harold Olney; Rami Younan
Journal:  J Gastrointest Oncol       Date:  2011-06

Review 2.  Cytoreductive Surgery and Peritonectomy Procedures.

Authors:  Sanket S Mehta; Aditi Bhatt; Olivier Glehen
Journal:  Indian J Surg Oncol       Date:  2016-02-03

Review 3.  Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases.

Authors:  Sanket S Mehta; Maxilliano Gelli; Deepesh Agarwal; Diane Goéré
Journal:  Indian J Surg Oncol       Date:  2016-02-10

4.  A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.

Authors:  Konstantinos Votanopoulos; Chukwuemeka Ihemelandu; Perry Shen; John Stewart; Gregory Russell; Edward A Levine
Journal:  J Surg Res       Date:  2012-03-10       Impact factor: 2.192

5.  Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin.

Authors:  Carlos Pérez-Ruixo; Belén Valenzuela; José Esteban Peris; Pedro Bretcha-Boix; Vanesa Escudero-Ortiz; José Farré-Alegre; Juan José Pérez-Ruixo
Journal:  AAPS J       Date:  2015-11-17       Impact factor: 4.009

Review 6.  Failure to rescue patients from early critical complications of oesophagogastric cancer surgery.

Authors:  Elroy P Weledji; Vincent Verla
Journal:  Ann Med Surg (Lond)       Date:  2016-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.